23,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
payback
12 °P sammeln
  • Broschiertes Buch

Tuberculosis is an emergent burden for the public health, with costly treatment. When inadequate treatment and poor adherence are associated with primary TB, tubercle bacilli resistant to first line drugs arise. The combined resistance to both Isoniazid and Rifampicin, here termed multi-drug resistant tuberculosis (MDR-TB). MDR-TB is emerging since 1990s and constitute one of the major challenges to TB eradication, in addition to HIV pandemic. A retrospective study to evaluate the clinical management of MDR-TB and features has been conducted on 154 patients admitted in Kabutare Hospital,…mehr

Produktbeschreibung
Tuberculosis is an emergent burden for the public health, with costly treatment. When inadequate treatment and poor adherence are associated with primary TB, tubercle bacilli resistant to first line drugs arise. The combined resistance to both Isoniazid and Rifampicin, here termed multi-drug resistant tuberculosis (MDR-TB). MDR-TB is emerging since 1990s and constitute one of the major challenges to TB eradication, in addition to HIV pandemic. A retrospective study to evaluate the clinical management of MDR-TB and features has been conducted on 154 patients admitted in Kabutare Hospital, Rwanda the period of 2009-2010. The results of these investigations can be found in this book.
Autorenporträt
Bernardin est un pharmacien qui travaille dans le secteur humanitaire et a de l'expérience dans la gestion de la chaîne d'approvisionnement en médicaments et l'amélioration de la qualité des soins de santé dans les hôpitaux. Il a été bénévole de différents groupes de base universitaires. Il a assuré les rôles de gestion des services de pharmacie dans un hôpital public et dans le programme national de lutte contre le VIH/SIDA au Rwanda.